Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAK 214

Drug Profile

TAK 214

Alternative Names: Norovirus bivalent vaccine - Takeda; Norovirus bivalent VLP vaccine; Norovirus GI.1/GII.4 bivalent VLP vaccine; Norovirus IM vaccine - Takeda; Norovirus intramuscular vaccine - Takeda; TAK-214

Latest Information Update: 24 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LigoCyte Pharmaceuticals
  • Developer Takeda
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Norovirus infections

Most Recent Events

  • 24 Jun 2019 TAK 214 is still in phase II trials for Norovirus infections (Takeda website, June 2019)
  • 03 Oct 2018 Immunogenicity data from a phase II trial in Norovirus infections presented at the IDWeek (IDW-2018)
  • 20 Jun 2018 Takeda completes a phase II trial for Norovirus infections (In children, In infants, Prevention) in Panama, Colombia, Finland (IM) (NCT02153112)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top